VIFOR-PHARMA-GROUP
14.5.2020 17:37:12 CEST | Business Wire | Press release
Regulatory News:
At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
In view of the current situation and based on Art. 6a of Ordinance 2, issued by the Swiss Federal Council, regarding measures against containment of the coronavirus (COVID-19), shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 69% of the share capital was represented.
Shareholder approvals
Shareholders approved the 2019 Vifor Pharma Annual Report, the Vifor Pharma Ltd. 2019 Annual Financial Statements, and the Vifor Pharma Group 2019 Consolidated Financial Statements as well as an extension of the Authorized Capital until 14 May 2022 by approving the respective amendment to the Articles of Association. The maximum possible 2020 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2019 Remuneration Report in a consultative vote. Shareholders discharged the members of the Board of Directors and the Corporate Executive Committee for the financial year 2019. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders on 20 May 2020.
Board of Directors re-elections
The Annual General Meeting re-elected all members proposed and elected Gilbert Achermann as new member of the Board of Directors. Shareholders also elected Jacques Theurillat as new Chairman of the Board of Directors, succeeding Etienne Jornod who decided not stand for re-election after 25 years. The Board of Directors sincerely thanks him for many years of distinguished service and recognized his long-standing and successful leadership by appointing him as Honorary Chairman.
The Board of Directors is now composed of the following members: Jacques Theurillat (Chairman), Gilbert Achermann, Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, Dr. Sue Mahony, Kim Stratton and Dr. Gianni Zampieri.
Remuneration Committee confirmed
The following members of the Board of Directors were re-elected to the Remuneration Committee for a term of one year: Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, and Dr. Sue Mahony.
Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Intersolar Europe: European Solar Industry Responds to Market Changes: Focus on Hybrid PV and New Financing Models24.2.2026 14:30:00 CET | Press release
The European solar market continues to grow. According to SolarPower Europe’s latest European Market Outlook, 2025 marked another strong year for photovoltaics (PV) within the European Union. When it comes to annual expansion rates, Germany is at the top of the list, followed by Spain, France, Italy and Poland. The importance of solar energy in meeting Europe’s power needs continues to grow. At the same time, many countries are changing their subsidies and financing models, creating new challenges for investors. While regulatory instruments, such as contracts for difference (CFDs), provide a new order, the industry is responding with market-based solutions, such as hybrid PV power plants and hybrid power purchase agreements (PPAs). Intersolar Europe offers guidance: At The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry at Messe München, trade visitors can experience innovations, discuss new business models and meet project developers, manufacturers a
LMR Unveils Tonka Bean CO₂ Absolute: Gourmand Excellence from Planet-Friendly Extraction24.2.2026 14:15:00 CET | Press release
True-to-nature gourmand richness achieved with renewable CO2 technology. IFF (NYSE: IFF) — LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—has introduced Tonka Bean CO₂ Absolute to its Conscious Collection, a line of 12 highly sustainable and traceable natural ingredients for perfumes and flavors. Tonka Bean CO₂ Absolute is a natural extract with a gourmand olfactive signature. This new addition to the perfumer’s palette is produced with renewable and recycled supercritical CO2 at IFF’s extraction site in Aubrac, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224233830/en/ Tonka Bean CO₂ Absolute extracted by LMR. “Our CO₂ extraction unit in Aubrac has enabled LMR to develop a collection of extracts that seamlessly blends sustainability with high hedonic profiles for perfumers," said Bertrand de Préville, general manager of LMR Naturals by IFF. "With the launch of To
NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP24.2.2026 14:00:00 CET | Press release
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/ Supporting stable, high-titer cell line development and seamless GMP advancement. The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and re
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 202624.2.2026 14:00:00 CET | Press release
-- The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer populations, supported by the favorable clinical, pharmacokinetic and dosimetry results from Phase 1b -- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ADVC001 in metastatic prostate cancer. ADVC001 is an investigational Lead-212-based prostate-specific membrane antigen (PSMA)-targeted alpha therapy. The study design will be showcased in a ‘Trials in Progress’ poster this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) in San Francisco, CA. The TheraPb Phase 2 is an open-label, randomized expansion study incorporating dose optimization strategies in three groups of patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). The study’s innovative d
Axelera AI Secures More Than $250 Million Funding on Global Commercial Growth24.2.2026 14:00:00 CET | Press release
European AI semiconductor leader earns backing from funds managed by Innovation Industries and SiteGround Capital along with EU institutions; edge-first architecture addresses AI's critical energy and cooling constraints Axelera AI, the European leader in AI acceleration hardware, announced its latest funding round led by Innovation Industries, with participation from prominent funds and accounts including BlackRock and SiteGround Capital as new investors, as well as existing investors Bitfury, CDP Venture Capital, European Innovation Council Fund, Federal Holding and Investment Company of Belgium (SFPIM), Invest-NL, Samsung Catalyst Fund, and Verve Investments. Axelera AI has attracted over $450 million in equity, grants and venture debt since incorporating in July 2021. The largest investment ever in an EU AI semiconductor company comes as Axelera ships to its 500th global customer across physical AI and edge AI in industries including defense and public safety, industrial manufactur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom